According to the Zhitong Finance App, Nanxin Pharmaceutical (688189.SH) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 112 million yuan, a year-on-year decrease of 63.12%. Net profit attributable to shareholders of listed companies was 37.665 million yuan, a year-on-year decrease of 69.95%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was $3.292,900, a year-on-year decrease of 79.62%.